All AbMole products are for research use only, cannot be used for human consumption.
In vitro: DLBCL cells are exposed to 50 μM FX1 for 30 minutes. FX1 profoundly reduces recruitment of BCOR and SMRT to all 3 BCL6 target genes, but not at a negative control locus. There is little presence of SMRT at these loci in the BCL6-negative DLBCL cell line, which is not affected by FX1. The superior potency of FX1 versus 79-6 in disrupting BCL6 binding to SMRT is evident when these small molecules are compared head to head in quantitative ChIP assays in DLBCL cells after treatment with 50 μM FX1 for 6 hours. DLBCL cells are exposed to FX1 and mRNA is collect at 4 serial time points. FX1 almost invariantly induces significant derepression of these genes as compare with vehicle in 2 independent DLBCL cell lines.
In vivo: Spleens in FX1-treating mice are macroscopically indistinguishable from vehicle controls. Total B cell abundance measured by flow cytometry is unaffected by FX1. GC B cells (GL7+FAS+B220+) are significantly depleted by exposure to FX1. Splenic architecture is examined by IHC. Staining with B220 antibody reveals normal B cell follicular structures, whereas staining for the GC B cell-specific marker peanut agglutinin shows profound loss of GCs. The half-life is estimated to be approximately 12 hours. Finally, whether FX1 can induce toxic effects in mice is assessed. No signs of toxicity, inflammation, or infection are evident from H&E-stained sections of lung, gastrointestinal tract, heart, kidney, liver, spleen, and bone marrow of the fixed organs from mice treated with FX1 compare with vehicle.
| Cell Experiment | |
|---|---|
| Cell lines | DLBCL cells |
| Preparation method | Quantitative ChIP is performed in SUDHL-6 cells exposed to FX1 (black bars) or vehicle (white bars) in DLBCL cells using antibodies for BCL6, SMRT, BCOR, or IgG control to enrich for known BCL6 binding sites in the CD69, CXCR4, and DUSP5 loci, or a negative control region. |
| Concentrations | 50 μM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | SCID mice bearing SUDHL-6 xenografts |
| Formulation | 35% PEG-300, 5% Tween-80, 65% Dextrose 5% |
| Dosages | 50 mg/kg |
| Administration | i.p. |
| Molecular Weight | 368.82 |
| Formula | C14H9ClN2O4S2 |
| CAS Number | 1426138-42-2 |
| Solubility (25°C) | 30 mg/mL in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| GAPDH-IN-1
GAPDH-IN-1 (GAPDH Inhibitor Compound F8) is a covalent inhibitor of GAPDH (IC50 = 39.31 µM). It viability of, and glucose metabolism in, HEK293 cells in a concentration-dependent manner. |
| O-acetylcamptothecin
O-acetylcamptothecin is a derivative of camptothecin, a naturally occurring alkaloid extracted from the bark of the Chinese tree Camptotheca acuminata. Camptothecin and its derivatives are primarily known for their potent anticancer properties, particularly through their action as inhibitors of topoisomerase I, an enzyme critical for DNA replication and transcription. |
| 10-hydroxystearic acid
10-hydroxystearic acid is a hydroxy fatty acid. |
| SB-T-1214
SB-T-1214 is a new-generation taxoid. SB-T-1214 possesses significant activity against colon cancer spheroids induced by and enriched with drug resistant tumorigenic CD133high/CD44high cells and efficiently inhibited expression of the majority of stem cell-related genes. |
| NG-497
NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
